LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Stool Samples Provide Marker for Bowel Disease

By LabMedica International staff writers
Posted on 08 Apr 2014
Print article
Image: The SRI 8610C gas chromatograph (Photo courtesy of SRI Instruments).
Image: The SRI 8610C gas chromatograph (Photo courtesy of SRI Instruments).
A novel method for distinguishing different types of bowel disease using the stool samples of patients has been created which is an ideal noninvasive testing method for the diagnosis of gastro-intestinal diseases.

The method works by analyzing the chemical compounds emitted from the samples and could provide cheaper, quicker and more accurate diagnoses, at the point of care, for a group of diseases that have up until recently been very hard to differentiate.

Scientists at the University of the West of England (Bristol, UK) obtained 182 stool samples from patients with inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) between October 2010 and October 2011. IBS samples were obtained from patients with diarrhea predominant (IBS-D), constipation predominant (IBS-C), and the alternating between the two syndrome (IBS-A). IBD samples were obtained from patients with both ulcerative colitis (UC) and Crohn's disease (CD). Control samples were collected from healthy patients.

The test was based on the volatile organic compounds (VOCs) emitted from their stool samples, which act as a proxy for conditions in the gastrointestinal tract and provide a unique profile, or fingerprint, for the different bowel diseases. The investigators developed the method using an SRI 8610C gas chromatograph (SRI Instruments, Torrance, CA, USA) coupled to a metal oxide sensor system with pattern recognition software.

The results showed that patients with IBD could be distinguished from healthy controls with an accuracy of 79%. The method was able to distinguish IBD from IBS with an accuracy of 76%. Differentiating patients with IBS from healthy controls using VOCs appeared to be more difficult and could only be achieved with an accuracy of 54%. The reasons could be because IBS is a functional disorder as opposed to a structural disorder, so the changes in composition of VOCs in the stool samples would not be as great, producing a very similar pattern to healthy controls.

In conclusion, the authors stated that: “Our work has demonstrated that a low-cost device based on VOC analysis could be used to potentially diagnose, and differentiate, IBS and IBD at the point of care. We will continue to study fecal volatiles as a way of detecting IBS, IBD and other gastrointestinal conditions and continue to develop our techniques further. If we're able to produce results that exceed current commercial methods, then our technique could be added to the growing number of medical tests that use VOC analysis as a diagnostic tool.” The study was published on March 27, 2014, in the Journal of Breath Research.

Related Links:

University of the West of England 
SRI Instruments 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more